CClinicalTrials.gg
CompletedNCT05245981Updated Jan 31, 2023

Clinical Application of Mg Based Biodegradable Material for Fracture Fixation in the Adult Skeleton

A Phase 2/3 interventional study of BRI.MAG 2 in Fracture of Medial Malleolus, sponsored by Medical University of Graz. Completed at 1 site in Austria. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-01-31.

Sponsored by Medical University of Graz · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 6 months after the study started (first participant enrolled Jul 2018, registered Feb 2022).
Phase
Phase 2/3
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is a prospective, non-randomized trial for the treatment of fractures of the medial malleolus using lean, bioabsorbable, rare-earth element (REE) free, magnesium (Mg)-based biodegradable screws in the adult skeleton.

A total of 20 patients with isolated, bimalleolar, or trimalleolar ankle fractures were recruited between July 2018 and October 2019. Fracture reduction was achieved through bioabsorbable Mg-based screws composed of pure Mg alloyed with zinc (Zn) and calcium (Ca) (0.45 wt% Zn and 0.45 wt% Ca; ZX00). Visual analogue scale (VAS) and the presence of complications (adverse events) during follow-up (12 weeks) were used to evaluate the clinical outcomes. The functional outcomes were analyzed through the range of motion (ROM) of the ankle joint and the American Orthopaedic Foot and Ankle Society (AOFAS) score. Fracture reduction and gas formation were assessed using several plane radiographs.

Read the detailed description

The pilot study was designed as a prospective, nonrandomized trial for the treatment of displaced fractures of the medial malleolus with a lean, REE-free, Mg-based biodegradable implant in the adult skeleton. The trial was conducted according to the Good Clinical Practice (ISO 14155:2011) standard and the Declaration of Helsinki.The study was performed at the Department of Orthopaedics and Trauma at the Medical University of Graz and approved by the ethics committee (28 - 071 ex 15/16). A total of 20 subjects were recruited and operated on by three experienced surgeons in the centre between July 2018 and October 2019. Inclusion focused on adults aged between 18 and 65 years presenting with a displaced isolated medial malleolus fracture, a bimalleolar ankle fracture, or a trimalleolar ankle fracture. Fracture displacement was defined as diastasis of the fracture in any direction of 2 mm or more. Exclusion criteria were pathological fractures, underlying diseases (particularly bone diseases, kidney diseases, diabetes mellitus), polytraumatized patients, and pregnant or breastfeeding women.Written informed consent was obtained from each patient before the surgery. All radiological data were stored in a picture archiving and communication system (PACS). Fractures were classified according to the Herscovici system.25

Description of the bioresorbable device used: Ultra-high pure Mg (99.999%) was alloyed with Zn and Ca (0.45 wt% Zn and 0.45 wt% Ca) at 750°C under a protective gas atmosphere. Prepared screws had a length of 40 mm and a diameter of 3.5 mm. Implants were threaded at the distal part for use as traction screws.

Surgery: All patients were operated in a supine position. In case of a bimalleolar or trimalleolar fracture, the fibular and the dorsal tibial fragments were treated before the medial malleolus. Subsequently, two parallel Kirschner wires perpendicular to the medial malleolar fracture line were positioned with fluoroscopic control. A cannulated drill bit with 2.7 mm width was used for preparing the hole. Subsequently, one wire was removed and the ZX00 compression screw was inserted into the hole. Final fixation of the fracture was achieved with the second bioabsorbable Mg screw after removal of the second wire. The insertion torque of the screws was limited at a force of 1.5 newton metre with a torque handle. In all patients, no additional implants other than the Mg screws were used for the fixation of the medial malleolus. Patients with bimalleolar fractures and trimalleolar fractures were fixed with titanium plates and screws. Moreover, patients were immobilized with an under-knee plaster cast four to six weeks postoperatively and encouraged to attempt full weight-bearing as tolerated. Ankle movement exercises were started immediately after removal of the plaster.

Assessments and measurements: For each subject, the study consisted of assessments conducted preoperatively, immediately after operation and postoperative followup visits. During follow-up, complications including vital signs, erythema, swelling, pain, secretions, wound healing disorders, wound infections, or implant infections were recorded. Pain was assessed using visual analogue scale (VAS). Blood analysis and detection of Ca and Mg were recorded. Functional outcomes were evaluated through range of motion (ROM) in dorsal and plantar flexion. Additionally, the American Orthopaedic Foot and Ankle Society (AOFAS) score was performed after three months. Anteroposterior and lateral ankle radiographs (X-rays) were used to evaluate the fracture union and loss of reduction during follow-up. Postoperative radiograph evaluation was performed by two independent radiologists.

The study was registered retrospectively on Clinicaltrials.gov.

02

Conditions studied

  • Fracture of Medial Malleolus

Browse trials for

03

In context

Fractures, Bone

2,261 studies on the registry are indexed under Fractures, Bone; 325 are open to participants now.

This study's enrollment of 20 is below the median of 69 across 1,482 interventional studies indexed under Fractures, Bone.

Browse Fractures, Bone studies →

Lead sponsor

Medical University of Graz is the lead sponsor of 459 studies on the registry; 98 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with a dislocated fracture of the medial malleolus. Dislocation is defined as diastasis of the fracture in any direction of 2 mm or more.
  • Otherwise healthy patients (women and men) in the age-group 18 to 65 years
  • Subject has been informed of the nature of the study, agrees to participate and signs the approved consent forms. Included in this procedure is the standard information about the operation procedure.
  • Subject is able and willing to comply with all assessments in the study
  • Female subject with child-bearing potential perform a pregnancy test

Exclusion criteria

Exclusion Criteria:

  • pathological fractures (f.e. bone cyst)
  • underlying diseases (particularly bone diseases, kidney diseases, diabetes mellitus)
  • poly-traumatized patient
  • multiple fractures at the same extremity
  • pregnant or breastfeeding women
  • inability or unwillingness to give informed consent
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    BRI.MAG 2

    Patients presenting with dislocated isolated or combined fracture of the medialis malleolus are eligible to receive the investigational device.

    Device: BRI.MAG 2

Interventions

  • DeviceBRI.MAG 2

    Patients presenting with dislocated isolated or combined fracture of the medialis malleolus, will be screened for eligibility. Every effort will be made to ensure eligibility of the patients prior to enrollment. 20 patients will be recruited for the study.

06

What researchers measure

Primary outcomes

  1. Safety: Absence of (Serious) Adverse Events (SAE) throughout the study

    (Serious) Adverse Events defined as: * Secondary (post-op) diastasis of the distal tibiofibular joint assessed by two plane x-rays * Secondary diastasis of the malleolus medialis assessed by two plane x-rays. * Infection of the osteosynthesis assessed clinically and/or radiologically with the presence of at least three of the following signs: clinically: pain, swelling, warmth and redness in the infected area, chills and fever x-rays: regional osteopenia, periosteal reaction/thickening, Codman's triangle, focal bony lysis, loss of bony trabecular architecture, new bone apposition

    Time frame: 3 years after surgery

  2. Primary Efficacy- Change of stability of the distal tibiofibular joint

    Stability of the distal tibiofibular joint reduced with two BRI.MAG screws assessed by two plane x-rays after surgery, at 2 weeks and at 6 weeks s and at 6 weeks

    Time frame: after surgery, at 2 weeks and at 6 weeks

  3. Primary Efficacy- Change of stability of the fracture of the medial malleolus

    Stability of the fracture of the medial malleolus reduced by two BRI.MAG screws assessed by two plane x-rays after surgery, at 2 weeks and at 6 weeks

    Time frame: after surgery, at 2 weeks and at 6 weeks

Secondary outcomes

  1. Procedural success - operation procedure

    no change of the operation procedure from conventional to biodegradable

    Time frame: 6 weeks

  2. Procedural success- complications

    Occurrence of interventional complications (break of material)

    Time frame: 6 weeks

07

Study locations

1 site
  • Medical University of Graz
    Graz, Styria 8036, Austria
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05245981
Lead sponsor
Medical University of Graz
Collaborators
Laura Bassi Fond; AUVA
Responsible party
Sponsor
First posted
Feb 18, 2022
Start date
Jul 9, 2018
Primary completion
Jan 17, 2023
Completion
Jan 17, 2023
Last update
Jan 31, 2023

Study contacts

Franz Josef Seibert, Prof.Dr.
principal investigator · Medical University of Graz, Departement of orthopaedics and traumatology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion